BUZZ - Starbucks shares fall; reports said it once considered acquiring Chipotle Mexican Grill
路透社2026/10/08 14:51On October 8, Starbucks (SBUX.O), the coffee chain brand, saw its stock price drop by as much as 6.66% to $87.35. According to sources cited by the Financial Times, the company had considered acquiring Chipotle Mexican Grill (CMG.N). The report states the progress of this acquisition plan remains unclear. Starbucks (SBUX) currently has a market value of about $39 billion. Chipotle’s (CMG) stock price surged as much as 8.55% to $33.40. Chipotle has not yet responded to a request for comment from Reuters. As of the close of the previous trading day, SBUX has risen about 10% so far this year, while CMG has dropped 12% year-to-date. (For the benefit of non-English speakers, Reuters has automated translation of its reports into several other languages. Since automated translations may occasionally be inaccurate or lack the intended context, Reuters does not guarantee the accuracy of these translations and provides them solely for convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation.)
October 8 - ** Coffee chain brand Starbucks (SBUX.O) shares once fell by 6.66% to $87.35
** The Financial Times, citing sources, reported that the company had discussed plans to acquire (link) Mexican grill chain Chipotle CMG.N
** The report said the progress of the acquisition plan remains unclear
** Starbucks (SBUX) has a market capitalization of approximately $39 billion
** Chipotle (CMG) shares once surged by 8.55% to $33.40
** Chipotle has not yet responded immediately to a Reuters request for comment
** As of the close of the previous trading day, SBUX had risen about 10% year-to-date, while CMG had fallen 12% year-to-date
(To assist non-English speakers, Reuters has automatically translated its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of these texts, which are provided solely for readers' convenience. Reuters accepts no liability for any damage or loss arising from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
